Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study
Background. The apolipoprotein E (APOE) polymorphisms are associated with cardiovascular (CV) disease, but its interaction with type 2 diabetes mellitus (T2DM) long-term incidence is unknown. We investigated the association between APOE genotype and long-term (i) CV events and (ii) T2DM incidence in...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | Journal of Lipids |
Online Access: | http://dx.doi.org/10.1155/2019/1698610 |
id |
doaj-2989d305f7264d3a855d83aeede51c67 |
---|---|
record_format |
Article |
spelling |
doaj-2989d305f7264d3a855d83aeede51c672020-11-24T21:54:39ZengHindawi LimitedJournal of Lipids2090-30302090-30492019-01-01201910.1155/2019/16986101698610Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational StudyCátia Santos-Ferreira0Rui Baptista1Manuel Oliveira-Santos2Regina Costa3José Pereira Moura4Lino Gonçalves5Department of Cardiology, Coimbra University Hospital Center, Coimbra, PortugalDepartment of Cardiology, Coimbra University Hospital Center, Coimbra, PortugalDepartment of Cardiology, Coimbra University Hospital Center, Coimbra, PortugalDepartment of Internal Medicine, Coimbra University Hospital Center, Coimbra, PortugalDepartment of Internal Medicine, Coimbra University Hospital Center, Coimbra, PortugalDepartment of Cardiology, Coimbra University Hospital Center, Coimbra, PortugalBackground. The apolipoprotein E (APOE) polymorphisms are associated with cardiovascular (CV) disease, but its interaction with type 2 diabetes mellitus (T2DM) long-term incidence is unknown. We investigated the association between APOE genotype and long-term (i) CV events and (ii) T2DM incidence in a Southern European primary prevention cohort. Methods. We assessed individual APOE genotypes in a total of 436 patients followed at a lipid clinic, with a 15-year median follow-up time. We collected data on major CV events (CV death, myocardial infarction, and stroke) and T2DM development. Results. No differences were found regarding major CV event incidence among the different APOE genotypes. However, after excluding 39 patients with a prior history of T2DM, APOE2 carriers displayed a higher incidence of T2DM during follow-up (42.2%) than APOE3 (27.1%) and APOE4 (28.7%) carriers. The age-, sex-, triglycerides-, and statin usage-adjusted OR for T2DM incidence in APOE2 carriers was 1.8 (95%CI 1.1-2.9, p=0.03), compared with wild-type APOE3. To address the role of statins as a confounder, we analyzed T2DM incidence in statin-treated patients. Statin-treated APOE2 carriers also had a higher T2DM incidence (57.9%), in comparison with APOE3 homozygotes (31.6%) and APOE4 carriers (32.5%). After adjustment for confounding, APOE2 carriers on statins displayed a similar twofold increase in T2DM risk compared to APOE3 homozygotes (OR 2.1, 95%CI 1.1-4.0, p=0.03). Conclusion. Our findings suggest a twofold increase in T2DM incidence in APOE2 carriers. This may prompt for a specific glucose dysmetabolism follow-up that might be tailored on the APOE genotype.http://dx.doi.org/10.1155/2019/1698610 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cátia Santos-Ferreira Rui Baptista Manuel Oliveira-Santos Regina Costa José Pereira Moura Lino Gonçalves |
spellingShingle |
Cátia Santos-Ferreira Rui Baptista Manuel Oliveira-Santos Regina Costa José Pereira Moura Lino Gonçalves Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study Journal of Lipids |
author_facet |
Cátia Santos-Ferreira Rui Baptista Manuel Oliveira-Santos Regina Costa José Pereira Moura Lino Gonçalves |
author_sort |
Cátia Santos-Ferreira |
title |
Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study |
title_short |
Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study |
title_full |
Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study |
title_fullStr |
Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study |
title_full_unstemmed |
Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study |
title_sort |
apolipoprotein e2 genotype is associated with a 2-fold increase in the incidence of type 2 diabetes mellitus: results from a long-term observational study |
publisher |
Hindawi Limited |
series |
Journal of Lipids |
issn |
2090-3030 2090-3049 |
publishDate |
2019-01-01 |
description |
Background. The apolipoprotein E (APOE) polymorphisms are associated with cardiovascular (CV) disease, but its interaction with type 2 diabetes mellitus (T2DM) long-term incidence is unknown. We investigated the association between APOE genotype and long-term (i) CV events and (ii) T2DM incidence in a Southern European primary prevention cohort. Methods. We assessed individual APOE genotypes in a total of 436 patients followed at a lipid clinic, with a 15-year median follow-up time. We collected data on major CV events (CV death, myocardial infarction, and stroke) and T2DM development. Results. No differences were found regarding major CV event incidence among the different APOE genotypes. However, after excluding 39 patients with a prior history of T2DM, APOE2 carriers displayed a higher incidence of T2DM during follow-up (42.2%) than APOE3 (27.1%) and APOE4 (28.7%) carriers. The age-, sex-, triglycerides-, and statin usage-adjusted OR for T2DM incidence in APOE2 carriers was 1.8 (95%CI 1.1-2.9, p=0.03), compared with wild-type APOE3. To address the role of statins as a confounder, we analyzed T2DM incidence in statin-treated patients. Statin-treated APOE2 carriers also had a higher T2DM incidence (57.9%), in comparison with APOE3 homozygotes (31.6%) and APOE4 carriers (32.5%). After adjustment for confounding, APOE2 carriers on statins displayed a similar twofold increase in T2DM risk compared to APOE3 homozygotes (OR 2.1, 95%CI 1.1-4.0, p=0.03). Conclusion. Our findings suggest a twofold increase in T2DM incidence in APOE2 carriers. This may prompt for a specific glucose dysmetabolism follow-up that might be tailored on the APOE genotype. |
url |
http://dx.doi.org/10.1155/2019/1698610 |
work_keys_str_mv |
AT catiasantosferreira apolipoproteine2genotypeisassociatedwitha2foldincreaseintheincidenceoftype2diabetesmellitusresultsfromalongtermobservationalstudy AT ruibaptista apolipoproteine2genotypeisassociatedwitha2foldincreaseintheincidenceoftype2diabetesmellitusresultsfromalongtermobservationalstudy AT manueloliveirasantos apolipoproteine2genotypeisassociatedwitha2foldincreaseintheincidenceoftype2diabetesmellitusresultsfromalongtermobservationalstudy AT reginacosta apolipoproteine2genotypeisassociatedwitha2foldincreaseintheincidenceoftype2diabetesmellitusresultsfromalongtermobservationalstudy AT josepereiramoura apolipoproteine2genotypeisassociatedwitha2foldincreaseintheincidenceoftype2diabetesmellitusresultsfromalongtermobservationalstudy AT linogoncalves apolipoproteine2genotypeisassociatedwitha2foldincreaseintheincidenceoftype2diabetesmellitusresultsfromalongtermobservationalstudy |
_version_ |
1725866649239683072 |